Anti-thymocyte globulin (ATG)- or alemtuzumab-based graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic hematopoietic cell transplantation (HCT) for patients 40 years and older with acute lymphoblastic leukemia in first complete remission: a study from the EBMT Acute Leukemia Working Party. - Bug G; Labopin M; Byrne JL; Mielke S; Orchard K; Paneesha S; Potter V; Blaise D; Besley C; Snowden JA; Yakoub-Agha I; Clark A; et al. (Bone marrow transplantation, 2026)